[{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair\u00ae Breezhaler\u00ae (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Announces Second Novel Drug Candidate from Its Multi-Target Drug Discovery Collaboration with Pfizer has Started Clinical Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Breezhaler\u00ae Approval in the European Union as a Treatment for Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Approval in Japan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes that Enerzair\u00ae Breezhaler\u00ae has Been Recommended for Approval in the E.U for treating Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Aditum Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Aditum Bio to Advance mGlu5 NAM Clinical Program for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$10.0 million","newsHeadline":"Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$481.0 million","upfrontCash":"$44.0 million","newsHeadline":"Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"$3,290.0 million","upfrontCash":"$125.0 million","newsHeadline":"Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Metrion Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug discovery approaches to ion channels","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"InveniAI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Sosei Heptares\u2019 Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$731.0 million","upfrontCash":"$37.0 million","newsHeadline":"Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,280.0 million","upfrontCash":"$40.0 million","newsHeadline":"Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Sosei Heptares
PF-07081532 was discovered by Pfizer scientists during a multi-target research collaboration in which Pfizer had access to Sosei Heptares proprietary StaR® (stabilized receptor) technology. PF-07081532 has successfully completed Phase 1 clinical studies conducted by Pfizer.
This new agreement will leverage Sosei Heptares’ StaR® technology and structure-based drug design (SBDD) platform and Lilly’s extensive drug development and commercialization expertise as well as its therapeutic area expertise in diabetes and metabolic diseases.
Sosei Heptares and AbbVie entered into the discovery collaboration and option-to-license agreement to discover, develop and commercialize novel small molecule medicines that modulate GPCR targets of interest to AbbVie.
The focus of the agreements is to apply the innovative technologies and research capabilities of the respective academic groups to identify, validate and prioritize key GPCRs driving gastrointestinal and immune disorders, including IBD, as targets for SBDD.
NBI-1117568 is an investigational, oral, muscarinic M4 selective agonist. Muscarinic receptors are central to brain function and validated as drug targets in psychosis and cognitive disorders.
NBI-1117568 (previously known as HTL-0016878 ) is an oral, selective muscarinic M4 receptor agonist in development for the treatment of schizophrenia and other neuropsychiatric disorders. Clinical studies completed to date have shown NBI-1117568 to be generally well tolerated.
New strategic collaboration of AbbVie leverages Sosei Heptares’ StaR® technology and SBDD platform to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.
The funding will be used to advance the pre-clinical development of the SH-879, Company’s novel oral anti-viral small molecules targeting the main protease of SARS-CoV-2 (Mpro), an enzyme critical to SARS-CoV-2 replication, as potential treatments for COVID-19.
Under the collaboration, companies will develop and commercialize novel muscarinic receptor agonists including HTL-0016878. Neurocrine Biosciences will gain access to Sosei Heptares’ portfolio of clinical and preclinical subtype-selective M1, M4, and dual receptor agonists.
The objective of the collaboration is to identify new therapeutic product concepts for immune diseases where an AI and ML based approach can be applied to generate compelling evidence for the role of G-protein coupled receptors (GPCRs) in relevant immunomodulatory pathways.
Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
